drugset / Trial / NCT06356571
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Timeline
- Start
- 2025-03-17
- Primary completion
- 2027-01-08
- Completion
- 2027-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isatuximab | Monoclonal antibody | — | Subcutaneous |
| Background | Acetaminophen | Small molecule | — | Oral |
| Background | Carfilzomib | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Diphenhydramine | Small molecule | — | Oral |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |
| Background | Montelukast | Other / unclassified | — | Oral |